CARVYKTI hits profitability, but leadership turnover adds new questions
- Legend achieved its first quarter of adjusted net income profitability with $63 million in Q2 2026.
- Earlier-line use continues to grow, with second to fourth line patients driving more than 70% of U.S. volume.
- Outpatient administration now accounts for roughly 60% of the mix, which helps scale but creates slight margin pressure.
- The sudden departure of long-time CEO Ying Huang in Q3 2026 introduces unexpected execution risk.
- The in vivo platform was clinically validated, with LB2501 showing a 100% response rate at dose level 2.
A strong drug reaching scale
Legend's bull case relies on CARVYKTI becoming a sustainably profitable commercial juggernaut in multiple myeloma. That case took a big step forward in Q2 2026 when the company reported its first quarter of adjusted net income profitability. Outpatient administration is reaching about 60%, making the therapy easier for community hospitals to adopt.
Growth is moving deeper into earlier treatment. Second to fourth line patients now make up over 70% of U.S. volume. Furthermore, the company's newer in vivo pipeline showed major derisking data, giving Legend a path to future growth beyond a single drug.
The bear case centers on execution and competition. The rapid shift to outpatient administration is expected to dip gross margins to the low 50s in Q3. More importantly, the sudden departure of CEO Ying Huang introduces leadership uncertainty during a critical scaling phase. With competitor anito-cel facing a PDUFA date in late 2025, the company will have to defend its community hospital moats.
One partner, one main product
Legend makes money mainly through its Janssen collaboration for CARVYKTI. Outside China, the companies share pre-tax profits and losses equally. In Greater China, Legend keeps or bears 70% of pre-tax profits or losses.
Janssen books sales in most markets, while Legend records its share as collaboration revenue. In 2025, collaboration revenue was $944.8 million out of total revenue of $1.0289 billion. This one product defines the financial profile.
The model reached a turning point in Q2 2026, achieving adjusted net income profitability. The outpatient strategy is a key part of the story, as treating patients outside the hospital drives volume. However, this mix shift introduces slight variations in gross margin dynamics.
CARVYKTI first, pipeline later
CARVYKTI
CARVYKTI is Legend's core approved therapy for multiple myeloma, commercialized globally with Janssen. It generated $657 million in global net trade sales in Q2 2026.
CARTITUDE-5 and CARTITUDE-6
These trials push CARVYKTI into earlier myeloma treatment settings, aiming to widen the patient pool.
LB2501
An in vivo CD19/CD20 program for non-Hodgkin lymphoma. It recently showed a 100% objective response rate at dose level 2, validating the in vivo platform.
LB2505
An in vivo BCMA-targeted therapy. It is entering a clinical study in China subject to the collaboration with Janssen.
LB2102 and solid tumor work
Legend licensed LB2102, a DLL3-focused CAR-T program for small cell lung cancer, to Novartis. Early data showed a 28.6% objective response rate.
Revenue is highly concentrated
The mix is based on fiscal 2025 revenue in Legend's Form 20-F. Collaboration revenue tied to CARVYKTI made up almost all sales.
What could break the thesis
Leadership transition stumbles
High impact · Medium oddsCEO Ying Huang stepped down in Q3 2026, replaced by Interim CEO Alan Bash. While management insists the strategy remains the same, a sudden change at the top creates execution risk during a rapid scaling phase.
Outpatient shift hurts margins
Medium impact · Medium oddsThe growing share of outpatient administration is expected to push Q3 gross margins down to the lower 50% range. If margins do not rebound, the profitability narrative could weaken.
Anito-cel pressures the market
Medium impact · Medium oddsArcellx and Gilead's anito-cel faces an FDA decision in late 2025. A clean approval and strong launch could challenge CARVYKTI's position in community oncology networks.
Community rollout stalls
High impact · Medium oddsThe next leg of growth depends on reaching more community hospitals and local oncology practices. If local sites cannot handle referrals or logistics, demand may grow slower than expected.
In one breath
What is Legend Biotech best known for?
Legend is best known for CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma. It is the company's first and only approved product.
How does Legend Biotech make money?
Most revenue comes from the Janssen collaboration for CARVYKTI. The two companies share profits and losses, and Legend books its share as collaboration revenue.
Is Legend Biotech profitable?
Yes, the company achieved its first quarter of adjusted net income profitability in Q2 2026, recording $63 million in adjusted net income.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Legend Biotech Corporation in Finn's Biotechnology industry ranking.
